Download PDF
TumorDiagnostik & Therapie 2020; 41(02): 96-98
DOI: 10.1055/a-1074-5056
Schwerpunkt Internistische Nachsorge

Endokrine Folgen einer Tumortherapie

Reinhard Merz
› Further Information
Also available at
    Permissions and Reprints

Endokrine Spätfolgen können die Lebensqualität nach einer Tumortherapie erheblich beeinflussen. Je nach Tumorentität und Therapieform können verschiedene Stoffwechselfunktionen davon betroffen sein. Dieser Beitrag gibt einen Überblick.

Publication History

Article published online:
02 March 2020

© Georg Thieme Verlag KG
Stuttgart · New York

 

  • Literatur

  • 1 Brignardello E, Felicetti F, Castiglione A. et al. Endocrine health conditions in adult survivors of childhood cancer: the need for specialized adult-focused follow-up clinics. Eur J Endocrinol 2013; 168: 465-472
    CrossrefPubMedGoogle Scholar
  • 2 Skakkebaek NE, Rajpert-De Meyts E, Main KM. Testicular dysgenesis syndrome: an increasingly common developmental disorder with environmental aspects. Hum Reprod 2001; 16: 972-978
    CrossrefPubMedGoogle Scholar
  • 3 Bandak M, Jorgensen N, Juul A. et al. Testosterone deficiency in testicular cancer survivors – a systematic review and meta-analysis. Androl 2016; 4: 382-388
    CrossrefPubMedGoogle Scholar
  • 4 Fossa SD, Fung C, Dahl AA. Langzeitfolgen nach Behandlung testikulärer Malignome. Onkologe 2018; 24: 802-808
    CrossrefPubMedGoogle Scholar
  • 5 Loren AW, Mangu PB, Beck LN. et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013; 31: 2500-2510
    CrossrefPubMedGoogle Scholar
  • 6 Brydoy M, Fossa SD, Klepp O. et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97: 1580-1588
    CrossrefPubMedGoogle Scholar
  • 7 Schover LR. Premature ovarian failure and its consequences: vasomotor Symptoms, sexuality, and fertility. J Clin Oncol 2008; 26: 753-758
    CrossrefPubMedGoogle Scholar
  • 8 Partridge AH, Ruddy KJ, Gelber S. et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2010; 94: 638-644
    CrossrefPubMedGoogle Scholar
  • 9 Zavos A, Valachis A. Risk of chemotherapy-induced amenorrhea in patients with breast cancer: a systematic review and meta-analysis. Acta Oncol 2016; 55: 664-670
    CrossrefPubMedGoogle Scholar
  • 10 Furlanetto J, Thode C, Bassy M. et al. Chemotherapy-induced ovarian failure (CIOF) in young women with early breast cancer (EBC). J Clin Oncol 2017; 35 (Suppl. 15) 10068
    CrossrefPubMedGoogle Scholar
  • 11 Burstein HJ, Lacchetti C, Anderson H. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J Clin Oncol 2016; 34: 1689-1701
    CrossrefPubMedGoogle Scholar
  • 12 Francis PA, Pagani O, Fleming GF. SOFT and TEXT investigators and the international breast cancer study group. et al. Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 2018; 379: 122-137
    CrossrefPubMedGoogle Scholar
  • 13 Lambertini M, Moore HCF, Leonard RCF. et al. Gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in premenopausal patients with early breast cancer: a systematic review and meta-analysis of individual patient-level data. J Clin Oncol 2018; 36: 1981-1990
    CrossrefPubMedGoogle Scholar
  • 14 Hersant B, SidAhmed-Mezi M, Belkacemi Y. et al. Efficacy of injecting platelet concentrate combined with hyaluronic acid for the treatment of vulvovaginal atrophy in postmenopausal women with history of breast cancer: a phase 2 pilot study. Menopause 2018; 25: 1124-1130
    CrossrefPubMedGoogle Scholar
  • 15 Harris BS, Bishop KC, Kuller JA. et al. Hormonal Management of Menopausal Symptoms in Women With a History of Gynecologic Malignancy. Menopause 2019; DOI: 10.1097/GME.0000000000001447.
    CrossrefPubMedGoogle Scholar
  • 16 Loibl S, Seiler S. Schwangerschaft nach einer Tumorerkrankung. Gyn Endokrinol 2019; 17: 65-70
    PubMedGoogle Scholar
  • 17 Denzer C. Endokrinologische Nachsorge nach onkologischen Erkrankungen im Kindes- und Jugendalter, AWMF-Leitlinie 2014. www.awmf.org/leitlinien/detail/ll/025-030.html
    PubMedGoogle Scholar
  • 18 Sklar C, Whitton J, Mertens A. et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000; 85: 3227-3232
    PubMedGoogle Scholar
  • 19 Gebauer J, Higham C, Langer T. et al. Long-term Endocrine and Metabolic consequences of Cancer Treatment: A Systematic Review. Endocr Rev 2019; 40: 711-767
    CrossrefPubMedGoogle Scholar
  • 20 Chemaitilly W, Li Z, Huang S. et al. Anterior hypopituitarism in adult survivors of childhood cancers treated with cranial radiotherapy: a report from the St Jude Lifetime Cohort study. J Clin Oncol 2015; 33: 492-500
    PubMedGoogle Scholar
  • 21 Gebauer J, Spix C, Brabant G. et al. Endokrine Spätfolgen nach onkologischer Therapie im Kindesalter. Onkologe 2018; 24: 790-796
    CrossrefPubMedGoogle Scholar
  • 22 Permert J, Ihse I, Jorfeldt L. et al. Improved glucose metabolism after subtotal pancreatectomy for pancreatic cancer. Br J Surg 1993; 80: 1047-1050
    CrossrefPubMedGoogle Scholar
  • 23 Lutz MP, Mai C, Hoffmann-Cornely M. Pankreaskarzinom und andere gastrointestinale Tumoren bei Diabetes mellitus. Diabetologe 2013; 9: 551-556
    CrossrefPubMedGoogle Scholar
  • 24 Aggarwal G, Ramachandran V, Javeed N. et al. Adrenomedullin is up-regulated in patients with pancreatic cancer and causes insulin resistance in beta ceiis and mice. Gastroenterol 2012; 143: 1510-1517
    CrossrefPubMedGoogle Scholar
  • 25 http://www.nachsorge-ist-vorsorge.de/
    PubMed
  • 26 https://www.krebsgesellschaft.de/onko-internetportal/basis-informationen-krebs/leben-mit-krebs/alltag-mit-krebs/langzeitueberleben-nach-krebs-wie-lange-ist-ein-k.html
    PubMed